MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock
$159,999,996
Proceeds from options
exercised for common stock
$101,497
Proceeds from warrants
exercised for common stock
$1,683
Net cash
provided/(used in) by financing...
$150,153,362
(205730.38%↑ Y/Y)
Canceled cashflow
$9,949,814
Net
increase/(decrease) in cash and cash...
$7,837,830
(413.05%↑ Y/Y)
Canceled cashflow
$142,315,532
Payment of fees for
issuance of common stock
$9,817,890
Atm fees
$131,924
(80.67%↑ Y/Y)
Sale of short-term
investments
$56,628,855
(147.85%↑ Y/Y)
Stock appreciation
rights compensation
$4,019,150
(14436.33%↑ Y/Y)
Stock-based compensation
$1,859,089
(-76.55%↓ Y/Y)
Accounts payable
$840,246
(130.35%↑ Y/Y)
Unrealized loss/(gain) on
short-term investments
-$707,354
(-598.37%↓ Y/Y)
Other receivable
-$201,298
Accrued expenses
$150,000
(106.28%↑ Y/Y)
Realized loss/(gain) on
short-term investments
-$47,162
(-142.81%↓ Y/Y)
Net cash (used
in)/provided by investing...
-$117,641,611
(-633.81%↓ Y/Y)
Net cash used in
operating activities
-$24,673,921
(-0.84%↓ Y/Y)
Canceled cashflow
$56,628,855
Canceled cashflow
$7,824,299
Purchase of short-term
investments
$174,270,466
(21431.49%↑ Y/Y)
Net loss
-$31,966,141
(-16.55%↓ Y/Y)
Prepaid expenses and
other assets
$319,869
(177.67%↑ Y/Y)
Back
Back
Cash Flow
RELMADA THERAPEUTICS, INC. (RLMD)
RELMADA THERAPEUTICS, INC. (RLMD)
source: myfinsight.com